ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more
ABL Bio Inc (298380) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.151x
Based on the latest financial reports, ABL Bio Inc (298380) has a cash flow conversion efficiency ratio of -0.151x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-27.56 Billion) by net assets (₩182.22 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ABL Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how ABL Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ABL Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABL Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSC Financial Co. Ltd
F:CS0
|
0.131x |
|
China XD Electric Co Ltd
SHG:601179
|
0.024x |
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
|
Mohawk Industries Inc
NYSE:MHK
|
0.055x |
|
Balchem Corporation
NASDAQ:BCPC
|
0.054x |
|
LEG Immobilien SE
PINK:LEGIF
|
0.005x |
|
Federal Hme 6.55 Pf
OTCQB:FMCKI
|
0.037x |
|
Lithia Motors Inc
NYSE:LAD
|
0.024x |
Annual Cash Flow Conversion Efficiency for ABL Bio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of ABL Bio Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩167.28 Billion | ₩-69.40 Billion | -0.415x | -8.37% |
| 2023-12-31 | ₩74.08 Billion | ₩-28.36 Billion | -0.383x | -136.90% |
| 2022-12-31 | ₩69.51 Billion | ₩72.13 Billion | 1.038x | +242.99% |
| 2021-12-31 | ₩55.95 Billion | ₩-40.61 Billion | -0.726x | -39.12% |
| 2020-12-31 | ₩90.66 Billion | ₩-47.29 Billion | -0.522x | -188.67% |
| 2019-12-31 | ₩132.01 Billion | ₩-23.86 Billion | -0.181x | -123.90% |
| 2018-12-31 | ₩156.96 Billion | ₩-12.67 Billion | -0.081x | -197.13% |
| 2017-12-31 | ₩-85.96 Billion | ₩-7.14 Billion | 0.083x | -67.72% |
| 2016-12-31 | ₩-12.10 Billion | ₩-3.12 Billion | 0.257x | -- |